Integrated chemistry service provider NJ Bio announced that it expanded its Princeton laboratory and headquarters from 35,000 square feet to approximately 79,000 square feet.
This expansion is significant because it will allow the biopharmaceutical company to support the development and good manufacturing practice manufacturing of Antibody Drug Conjugates to meet the growing and urgent demand for clinical assets in this field.
NJ Bio is aggressively hiring synthetic organic, bioconjugation and oligonucleotide chemists, as well as analytical and quality assurance/quality control personnel to increase capacity and build up its GMP manufacturing capabilities. NJ Bio will also continue to operate its facility in Bristol, PA, with plans to further expand its GMP manufacturing capabilities.
“On behalf of NJ Bio employees and the board of directors, I am excited to announce the achievement of this significant milestone in our journey to providing expanded services and resources to support our clients’ clinical study programs,” Nareshkumar Jain, CEO And president of NJ Bio, said. “NJ Bio was granted the Best Contract Research Provider Award at the 8th World ADC Awards in October 2021 for being an outstanding partner to our clients, delivering high value for their research and development needs. Now, we aim to become an even more integrated partner to deliver on their clinical programs.
“We are laser-focused on setting up our state-of-the-art GMP manufacturing suites to become operational in 2022. This expansion will enable us to manufacture GMP-grade payload-linkers, drug candidates and antibody-drug conjugates for phase 1-3 clinical studies for our clients.”
This expansion of resources and facilities is an important step to transition NJ Bio from being a Contract Research Provider to a Contract Development and Manufacturing Organization, it added.
